Veru Schedules May 13 Financial Call, Eyes Phase 2b PLATEAU Interim Readout in Q1 2027
Veru will host its fiscal 2026 second-quarter financial call on May 13 at 8 a.m. ET, with a webcast and replay on its website. Its Phase 2b PLATEAU trial of enobosarm in 200 older obesity patients will report 36-week lean and fat mass interim data in Q1 2027 and topline results in Q4 2027.
1. Earnings Call Scheduled
Veru will present its fiscal 2026 second-quarter financial results and business update on May 13 at 8:00 a.m. ET. The live audio webcast and teleconference will be available via the company’s website, with an archived replay accessible for approximately three months.
2. Phase 2b PLATEAU Trial Design
The PLATEAU study is a randomized, double-blind, placebo-controlled trial evaluating enobosarm 3 mg in combination with semaglutide in roughly 200 patients aged 65 and older with obesity (BMI ≥ 35). Key endpoints include percent change in total body weight at 68 weeks, lean and fat mass by DXA, physical function, bone mineral density, HbA1c and insulin resistance.
3. Data Timeline and Outlook
An interim analysis of lean and fat mass changes at 36 weeks is scheduled for Q1 2027, followed by final topline data at 68 weeks in Q4 2027. Positive outcomes could support future Phase 3 development of oral enobosarm with GLP-1 receptor agonists.